SSY Group (02005.HK): Secures Production Registration Approval for New 2ml Specification of Potassium Dihydrogen Phosphate Complex Injection
NewTimeSpace News: SSY Group Limited (02005.HK) released a voluntary announcement on the 26th stating that it has obtained the drug production registration approval from the National Medical Products Administration of China (NMPA) for the new 2ml specification of Potassium Dihydrogen Phosphate Complex Injection. Classified as a Class 3 chemical drug, the product is deemed to have passed the consistency evaluation.
NewTimeSpace News: SSY Group Limited (02005.HK) issued a voluntary announcement today (January 26, 2026) announcing that it has successfully obtained the drug production registration approval issued by the National Medical Products Administration of China (NMPA) for the new 2ml specification of Potassium Dihydrogen Phosphate Complex Injection. Classified as a Class 3 chemical drug, the product is deemed to have passed the consistency evaluation, which means its quality and efficacy are consistent with those of the original research drug.
Potassium Dihydrogen Phosphate Complex Injection is a compound preparation. It is mainly indicated for correcting hypophosphatemia in adult and pediatric patients, and providing parenteral nutritional support for adult and pediatric patients in cases where oral or enteral nutrition is unavailable, insufficient or contraindicated.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY GROUP (02005.HK): Calcium Chloride API Approved for Registration by NMPA
- SSY GROUP(02005.HK): Bumetanide API Approved by NMPA
- SSY Group Limited (02005.HK): Calcium Levofolinate for Injection Approved, Deemed to Have Passed Consistency Evaluation
- SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
- SSY Group(02005.HK): Two APIs Approved by NMPA for Marketing
